Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study by Seyed Moayed Alavian, Mohammad Tasavon Gholamhoseini, Heidar Sharafi, Helena HL Borba, Asma Sabermahani, Behzad Hajarizadeh

“…Costs were converted to US dollars using purchasing power parity exchange rate ($PPP). All costs and outcomes were discounted at an annual rate of 3%.Results Among people with no cirrhosis, scenario 3 had the minimum cost, compared with which scenario 4 was cost-effective with an ICER of 4583 $PPP per QALY (willingness-to-pay threshold: 9,311 $PPP per QALY). …”
Get full text

Economic Evaluation of Robotic-assisted Radical Prostatectomy: A Systematic Review and Meta-analysis by Tanan Bejrananda, Win Khaing, Sajesh K. Veettil, Therdpong Thongseiratch, Nathorn Chaiyakunapruk

“…INBs were calculated in 2022 US dollars adjusted for purchasing power parity. A pooled analysis was performed using a random-effect model stratified by country income level. …”
Get full text

Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis by Lan Gao, Susan Brumby, Crystal Man Ying Lee, George Mnatzaganian, Suzanne Robinson, Helen Brown, Rachel Huxley, Anna Peeters, Dan Xu, James Boyd, Sean Randall, Adrienne O’Neil, Sangita Shakya, Sarah Gauci, Anita Shrestha, James Lucas

“…The pooled direct annual cost of CHD per patient varied from 4.9% to 137.8% of GDP per capita (Int$ purchasing power parity), with pooled percentage of 21.7% (95% CI 15.3, 28.1) for those with CHD. …”
Get full text